Advanced Bladder Cancer VL

Advancements in Treatments for Metastatic Urothelial Carcinoma (mUC) - Petros Grivas

Details
Alicia Morgans, MD, MPH, and Petros Grivas, MD, PhD, discuss the recent updates in the metastatic urothelial carcinoma (mUC) disease space. Together they discuss multiple presentations given during the virtual ASCO 2020 including the IMvigor010 trial. They discuss other adjuvant immunotherapy trials for mUC, as well as new results from IMvigor130 assessing biomarkers. Dr. Morgans and Dr. Grivas al...

JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg

Details
Cora Sternberg, MD, FACP, an investigator on the phase 3 JAVELIN Bladder 100 trial shares the study design, rationale, and key outcomes from the trial. The JAVELIN Bladder 100 trial is a phase 3 randomized study for maintenance avelumab therapy in patients who derived disease response or stabilization from first-line platinum-based chemotherapy for advanced urothelial cancer. In this conversation...

Assessing the Potential Cost-Effectiveness of the Addition of Atezolizumab to First-Line Platinum Chemotherapy in Advanced Urothelial Carcinoma - Ali Khaki

Details
Ali Khaki and Petros Grivas come together to discuss a study Ali Khaki presented at the 2020 ASCO meeting, on the cost-effectiveness of ateozlizumab added to first-line platinum chemotherapy for Advanced Urothelial Cancer. He with Dr. Grivas provides further insight into how this treatment plan was assessed, while also giving context regarding how cost-effectiveness is measured in cancer patients....

Progress in Bladder Cancer Research - Bishoy Faltas

Details
Bishoy Faltas joins Alicia Morgans to discuss the cutting edge aspects of his research on urothelial cancer. Dr. Faltas shares information on the CLONEVO Trial and his team’s initial efforts on integrating machine learning and artificial intelligence in the care of bladder cancer patients. Biographies: Bishoy M. Faltas, MD, Director of Bladder Cancer Research, Englander Institute for Precision Med...

IMvigor010 Primary Analysis from a Phase III Randomized Study of Adjuvant Atezolizumab versus Observation in High-Risk Muscle-Invasive Urothelial Carcinoma - Thomas Powles & Matthew Galsky

Details
The current standard of care for patients with localized muscle-invasive bladder cancer involves neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. Unfortunately, even with chemotherapy and surgery, cancer recurrence is common, with a 5-year survival rate of 50—60%. Thus, additional strategies are necessary to help patients achieve long term survival. Thomas Powles and Matthe...

JAVELIN Bladder 100: Avelumab for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma - Thomas Powles

Details
The phase III JAVELIN Bladder 100 trial was the first urothelial carcinoma plenary session at an ASCO annual meeting in the meeting's history and Thomas Powles lead principal investigator on the trial along with Matthew Galsky join Alicia Morgans sharing results of this trial. This was a maintenance trial where first-line treatment with avelumab extended the survival over best supportive care (BSC...

Controversial and Complex Cases in Urothelial Cancer - Srikala Sridhar

Details
Srikala (Kala) Sridhar joins Alicia Morgans to discuss the recent developments in urothelial cancer of the bladder and upper tract. The two discuss controversial issues in urothelial carcinoma from the American Joint Committee on Cancer (AJCC) staging to chemotherapy in upper tract disease, to bladder sparing recent clinical trial findings, and the impact of those trials on clinical practice treat...

The Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in MIBC - Andrea Necchi

Details
Andrea Necchi, a medical oncologist and Ewan Gibb a researcher at Decipher Biosciences joins Alicia Morgans as they discuss new findings related to bladder cancer and the impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer, an area of unmet need in bladder cancer. The trio cover patient sel...

Enfortumab Vedotin for Advanced Urothelial Carcinoma - Jonathan Rosenberg

Details
Alicia Morgans is joined by Peter O’Donnell and Jonathan Rosenberg to discuss enfortumab vedotin (EV). This offers a new mechanism of action and is the first antibody-drug conjugate (ADC). This represents a targeted therapy and was studied in metastatic urothelial carcinoma. In reviewing the clinical data and side effects of the drug, the three clinicians highlight the effectiveness and tolerabili...

Immunotherapy and Chemotherapy Use in Patients with Metastatic Bladder Cancer - Ronac Mamtani and Ravi Parikh

Details
In this conversation, Ronac Mamtani and Ravi Parikh join Alicia Morgans to discuss their recent work on bladder cancer outcomes and effectiveness research. They discuss immune checkpoint therapy versus carboplatin chemotherapy in patients with metastatic urothelial cancer (mUC). They also discuss the "Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cance...